Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 506943 | NSE Symbol : JBCHEPHARM | ISIN : INE572A01036 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
25-Oct-2024	06-Nov-2024	Quarterly Results	Quarterly Results Unaudited standalone and consolidated financial results for the quarter and half year ended on September 30, 2024 accompanied by limited review report (As Per BSE Announcement Dated on: 06/11/2024)
26-Jul-2024	08-Aug-2024	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2024. Unaudited Financial Results for the quarter ended on June 30, 2024 (As Per BSE Announcement dated on 08.08.2024)
10-May-2024	17-May-2024	Final Dividend	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve (i) the audited financial results for the year and quarter ended on March 31 2024; (ii) Consider and recommend Dividend on equity shares of the Company if any subject to approval of shareholders Recommendation of Final dividend of Rs. 6.75 per share of FV Re. 1(675%) for the FY 2023-24 (As Per BSE Announcement Dated on 15.05.2024)
30-Jan-2024	06-Feb-2024	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve (1) Unaudited Financial Results for the quarter and nine months ended on December 31 2023; and (2) Declaration of Interim Dividend if any for the financial year 2023-24 Declaration of interim dividend of Rs. 5.50 per share(550%) for Fy 2023-24 Appointment of Chief Financial Officer (As Per BSE Announcement Dated on 06.02.2024)
30-Oct-2023	07-Nov-2023	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2023 Unaudited financial results for the quarter and half year ended on September 30, 2023 accompanied by limited review report Appointment of Non-Executive Director Amendment to the Employee Stock Option Scheme Grant of Options under Employee Stock Option Scheme Allotment of Equity shares on exercise of Stock options pursuant to the Employee Stock Scheme (As Per BSE Announcement Dated on 07/11/2023) Newspaper cutting of extract of consolidated financial results for the quarter and half year ended on September 30, 2023 (As Per BSE Announcement Dated on 08/11/2023)
01-Aug-2023	09-Aug-2023	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2023. Unaudited Financial Results for the quarter ended on June 30, 2023 Setting-up of proposed step-down subsidiary Grant of options under Employee stock option scheme (As Per BSE Announcement Dated on 09.08.2023)
08-May-2023	24-May-2023	Final Dividend	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve audited financial results for the year and quarter ended on March 31 2023 recommend final Dividend on equity shares of the Company if any and consider and approve the proposal to sub-divide/split the equity shares Outcome of the Board meeting- Audited standalone and consolidate financial results for the year ended on March 31, 2023 (I) The Board considered and approved sub-division/split of existing equity shares (ii) Recommended a final dividend of Rs. 9.25 (462.50 %) per equity share (As Per BSE Announcement dated on 24.05.2023)
01-Feb-2023	08-Feb-2023	Quarterly Results	Interim Dividend & Quarterly Results Declaration of interim dividend of Rs. 8.50 per share of FV Rs. 2 (425%) for FY 2022-2023 (As Per BSE Announcement Dated on 08.02.2023)
14-Dec-2022	13-Dec-2022	Acquisitions	Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
03-Nov-2022	11-Nov-2022	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2022 In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find: 1. Unaudited standalone financial results for the quarter ended on September 30, 2022 accompanied by limited review report. 2. Unaudited consolidated financial results for the quarter ended on September 30, 2022 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4.18 p.m. and concluded at 6.12 p.m. (As Per BSE Announcement dated on 11.11.2022)
26-Jul-2022	04-Aug-2022	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2022 Outcome of meeting of Board of Directors - Unaudited Financial Results for the quarter ended June 30, 2022 (As Per BSE Announcement Dated 04.08.2022)
30-Jun-2022	29-Jun-2022	Acquisitions	Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
11-May-2022	26-May-2022	Final Dividend	Final Dividend & Audited Results J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 ,inter alia, to consider and approve (i) audited financial statements/annual financial results for the financial year ended on March 31, 2022; and (ii) recommendation of final dividend, if any, for financial year 2021-22. Recommendation of final dividend of Rs. 8 per share of FV Rs. 2 (400%) for FY 2021-22. 1. Audited standalone financial results for the year ended on March 31, 2022 accompanied by Auditors' Report. 2. Audited consolidated financial results for the year ended on March 31, 2022 accompanied by Auditors' Report. 3. Declaration of Unmodified opinion Recommendation of final dividend of Rs. 8 per share of FV Rs. 2 (400%) for FY 2021-22. (As Per BSE Announcement Dated on 26.05.2022)
07-Feb-2022	14-Feb-2022	Quarterly Results	J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve (i) unaudited financial results for the quarter ended December 31 2021; and (ii) declaration of Interim dividend if any for the financial year 2021-22 Outcome of meeting of Board of Directors-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 read with circular CIR/CFD/CMD/4/2015 dated September 9, 2015- Declaration of interim dividend of Rs. 8.50 per share of FV Rs. 2 (425%) for FY 2021-2022 Outcome of meeting of Board of Directors - Unaudited Financial Results for the quarter ended December 31, 2021 Outcome of meeting of Board of Directors-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 read with circular CIR/CFD/CMD/4/2015 dated September 9, 2015- Declaration of interim dividend of Rs. 8.50 per share of FV Rs. 2 (425%) for FY 2021-2022 (As Per BSE Announcement Dated on 14.02.2022)
26-Jan-2022	25-Jan-2022	Acquisitions	Acquisition of a portfolio of brands, for use and commercialization within India, from Sanzyme Private Limited Update on Acquisition of Brands and Related Assets from Sanzyme Private Limited (As Per BSE Announcement Dated on 01/02/2022)

1 2

LOGIN HERE

J B Chemicals & Pharmaceuticals Ltd

Board Meeting